Daratumumab+Pomalidomide+Dexamethasone (DPd) or Pomalidomide+Bortezomib+Dexamethasone (PVd), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide Exposed, Lenalidomide Refractory, 1,2,3 prior line of therapy, Teclistamab+Daratumumab, Phase 3, B-Cell Maturation Antigens (BCMA) Bispecific Antibody
### Instruction:
Identify the study with the following condition. 
### Input:
Daratumumab+Pomalidomide+Dexamethasone (DPd) or Pomalidomide+Bortezomib+Dexamethasone (PVd), Relapsed Refractory Multiple Myeloma (RRMM), Lenalidomide Exposed, Lenalidomide Refractory, 1,2,3 prior line of therapy, Teclistamab+Daratumumab, Phase 3, B-Cell Maturation Antigens (BCMA) Bispecific Antibody 
### Output:
Popular Name is MajesTEC-3, Study ID is NCT05083169